Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Serum Levels of Fibroblast Growth Factor 23 and Sclerostin in Relation to Serum Calcium Level in COVID 19 Patients

NCT05275491 is registered in ClinicalTrials.gov with Aswan University Hospital as lead sponsor.

NCT NCT05275491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05275491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Serum Levels of Fibroblast Growth Factor 23 and Sclerostin in Relation to Serum Calcium Level in COVID 19 Patients
Lead sponsor
Aswan University Hospital
Phase
Observational
Overall status
Completed
Start date
May 1, 2022
Completion date
February 1, 2023
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19